Company: ENTXW
Filing Date: 2025-05-30
Form Type: S-3
Source: 0001178913-25-002025
Chunk: 1

Company: Entera Bio Ltd.
Filing Date: 2025-05-30
Form: S-3
Chunk 1
---
 2025, pursuant to Rule 415(a)(5) promulgated under the Securities Act. This registration statement contains two prospectuses:

| • | a base prospectus which covers the offering, issuance and sale of up to $100.0 million of the registrant’s ordinary shares, debt securities, warrants, rights and units comprising any combination of these securities; and |

| • | a sales agreement prospectus covering the offering, issuance and sale of up to 30,000,000 ordinary shares that may be issued and sold pursuant to a sales agreement (the “Sales Agreement”) dated September 2, 2022, between the registrant and 
 Leerink Partners LLC.                                                                                                                                                                                                                           |

The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows the base prospectus. The ordinary shares that may be offered, issued and sold under the sales agreement prospectus are included in the $100.0 million of securities that may be offered, issued and sold by the registrant under the base prospectus. Upon termination of the Sales Agreement, any portion of the capacity included in the sales agreement prospectus that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus. The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED MAY 30, 2025 PROSPECTUS $100,000,000
Ordinary Shares, Debt Securities, Warrants, Rights and Units ENTERA BIO LTD. We may offer from time to time, in one or more offerings, ordinary shares, senior debt securities, subordinated debt securities, warrants, rights and units (collectively, the “securities”). The aggregate initial offering price of the securities that we may offer and sell under this prospectus will not exceed $100.0 million. We may offer and sell any combination of the securities described in this prospectus in different series, at times, in amounts, at prices and on terms to be determined at or prior to the time of each offering. This prospectus describes